The negative correlation between CEBPB expression and survival has also been demonstrated in other cancer types, such as high-grade serous ovarian cancer [52]. PPARGC1 was significantly downregulated in CTS and was a hub node in the PPI network, while its expression had a significant positive correlation with OS in colon cancer (Figure 6(a)). PPARGC1A was indicated as a tumor suppressor in colon cancer [53] and ovarian cancer [54], as well as a negative prognostic biomarker for CRC [37]. This evidence concerns the gene CEBPB and ovarian carcinoma.